RayBiotech, Inc. announced today that the application of its Mouse Cytokine Antibody Array has enabled the identification of key factors involved in the dissemination of leprosy infection in humans.
[More]
Ulcerative colitis (UC) and Crohn’s disease (CD) are both relapsing and remitting chronic diseases of bowel inflammation. By that I mean they flare and physicians try to get the flare under control and try to induce remission. However, despite a number of treatments available, they tend to relapse.
[More]
A new study by Los Alamos National Laboratory and University of Pennsylvania scientists defines previously unknown properties of transmitted HIV-1, the virus that causes AIDS.
[More]
Inflammation can be thought of as taking two major forms: acute or chronic. Acute inflammation, which can be painful, usually arises quickly and resolves quickly. It accompanies bacterial infections, traumatic injury and is useful to fight infections and promote healing.
[More]
University of Montreal researchers have discovered a novel molecular mechanism that can potentially slows the aging process and may prevent the progression of some cancers.
[More]
Genalyte, Inc. today announced its Maverick Detection System that simultaneously analyzes multiple antibodies and other proteins from a single small sample is now CE marked in Europe for research use.
[More]
Researchers at Charité - Universitätsmedizin Berlin have succeeded in demonstrating an association between delayed bone fracture healing and increased concentration of specific immune cells in the blood of the patient.
[More]
Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients, characterized by anorexia and unintended loss of appetite, progressive and continual weight loss, accompanied by generalized host tissue wasting, skeletal muscle atrophy, immune and metabolic dysfunction, and a greatly diminished quality of life.
[More]
Alnylam Pharmaceuticals a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTRsc, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
[More]
Stroke, heart attacks and numerous other common disorders result in a massive destruction of cells and tissues called necrosis. It's a violent event: As each cell dies, its membrane ruptures, releasing substances that trigger inflammation, which in turn can cause more cellular necrosis.
[More]
New research from Boston University School of Medicine (BUSM) reveals that B cells regulate obesity-associated inflammation and type 2 diabetes through two specific mechanisms.
[More]
Minerva Biotechnologies, a leading cancer and stem cell development company today announced a major breakthrough in human stem cell research.
[More]
Results from two studies published in Nature show that eating a salty diet may trigger the development of autoimmunity.
[More]
Increased dietary salt intake can induce a group of aggressive immune cells that are involved in triggering and sustaining autoimmune diseases.
[More]
Idera Pharmaceuticals, Inc. today announced the presentation of new data showing that its selective Toll-like receptor antagonists, IMO-3100 and IMO-8400, normalized the gene expression of important cytokines in a preclinical study of skin inflammation that is commonly used as a model of psoriasis.
[More]
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.
[More]
A study led by researchers at Boston University School of Medicine (BUSM) has identified epigenetic mechanisms that connect a variety of diseases associated with inflammation.
[More]
AMSBIO has announced a new 5-Clone Collagen Antibody-Induced Arthritis (CIAA) kit for the induction of Collagen-Induced Arthritis (CIA) in various species.
[More]
LEO Pharma A/S, a global pharmaceutical company specialising in dermatology, has entered into an exclusive research and license agreement with the German biotech company 4SC Discovery GmbH with the primary aim of jointly researching, developing and commercialising an oral treatment for inflammatory skin diseases such as psoriasis.
[More]
Scientists have uncovered an intriguing relationship between the risk for Kaposi’s sarcoma, smoking, and the use of highly active antiretroviral therapy.
[More]